NASDAQ:EXEL
Exelixis Stock News
$20.57
+0.160 (+0.784%)
At Close: May 24, 2024
Buying These 3 Stocks Could Be the Smartest Investing Move You Ever Make
03:00pm, Tuesday, 17'th May 2022 The Motley Fool
With thrilling long-term prospects, these three are excellent buys.
Exelixis (EXEL) Q1 2022 Earnings Call Transcript
07:00pm, Wednesday, 11'th May 2022 The Motley Fool
EXEL earnings call for the period ending March 31, 2022.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
06:08pm, Wednesday, 11'th May 2022 Zacks Investment Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
03:48pm, Wednesday, 11'th May 2022
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2022 Results - Earnings Call Transcript
10:15pm, Tuesday, 10'th May 2022
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Susan Hubbard - EVP of Public Affairs and IR Mike Morrissey - President and CEO Chris Senner
Exelixis (EXEL) Tops Q1 Earnings Estimates
09:25pm, Tuesday, 10'th May 2022 Zacks Investment Research
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Tops Q1 Earnings Estimates
06:49pm, Tuesday, 10'th May 2022
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Sector ETF report for FBT
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
03:37pm, Monday, 09'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Why Exelixis (EXEL) Might Surprise This Earnings Season
12:48pm, Monday, 09'th May 2022 Zacks Investment Research
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
12:47pm, Monday, 09'th May 2022
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Why Exelixis (EXEL) Might Surprise This Earnings Season
10:32am, Monday, 09'th May 2022
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
10:20am, Friday, 06'th May 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
10:20am, Wednesday, 04'th May 2022 Zacks Investment Research
Sector ETF report for XBI
